Synchron

Synchron was founded in 2012 by Thomas Oxley and Nicholas Opie, based on research into a distinctive and less invasive approach to brain-computer interface technology than competitors like Neuralink and Paradromics, which typically require open brain surgery to implant electrode arrays directly onto or into brain tissue: Synchron's Stentrode device is instead delivered through the patient's blood vessels using a minimally invasive procedure similar to techniques already well established in interventional cardiology and neurology, threading the device through blood vessels until it reaches a vein positioned near the brain's motor cortex, where it can then record neural signals associated with movement intention from within the blood vessel itself, without requiring the device to physically penetrate brain tissue. This vascular delivery approach, avoiding the need for open brain surgery, has let Synchron pursue human clinical trials of its technology somewhat earlier and with a differentiated risk profile relative to some competing brain-computer interface approaches requiring more invasive neurosurgical implantation procedures, and the company has successfully demonstrated its technology helping patients with severe paralysis, such as those with advanced ALS, control computer cursors, send text messages, and interact with various digital devices and applications using neural signals associated with their intended movements, even though those intended physical movements themselves are no longer possible given their underlying paralysis. Synchron has built a notable partnership with several major technology companies, including collaborating with Nvidia on AI integration for its brain-computer interface platform, and separately, has explored integration possibilities with other technology platforms to expand the range of digital devices and applications that patients using its Stentrode device could potentially control using neural signals alone. The company has positioned its less invasive vascular delivery approach as potentially offering a faster and lower-risk path toward eventual regulatory approval and broader patient access compared to brain-computer interface approaches requiring more invasive neurosurgical implantation. Synchron has raised substantial venture funding from investors including ARCH Venture Partners, Bezos Expeditions, and Chan Zuckerberg Initiative, positioning itself as a notable company in the emerging brain-computer interface industry.

News

5/25/2026

Synchron Raises $200 Million in Series D Funding

Synchron's $200 million Series D funding underscores strong investor confidence in its innovative neurotechnology, positioning the company to accelerate advancements in brain-computer interfaces and potentially reshape the future of neurological treatments and human-computer interaction.

Tech Times

InfotechLead

Tracxn

4/13/2026

Synchron Raises $200 Million in Series D Funding

Synchron's $200 million Series D funding underscores strong investor confidence in its innovative neurotechnology, positioning the company to accelerate advancements in brain-computer interfaces and potentially reshape the future of neurological treatments and human-computer interaction.

Time Magazine

Time Magazine

36 Kr

3/4/2026

Synchron Prepares for Pivotal Trial with Stentrode Technology

Synchron's pivotal trial with Stentrode technology could redefine neuroprosthetics, potentially unlocking significant market opportunities and attracting substantial investment in the burgeoning field of brain-computer interfaces.

WIRED

ForkLog

3DVF

2/19/2026

Synchron Advances Brain-Computer Interface Market with $4M Grant

Synchron's $4M grant accelerates the development of brain-computer interfaces, positioning the company to capitalize on a burgeoning market that could redefine neurological treatment and enhance human-computer interaction, attracting further investment and innovation.

PR Newswire

BI.no

1/6/2026

Synchron Expands BCI Trials, Revenue Expected at $703.7M

Synchron's expansion of BCI trials, coupled with projected revenues of $703.7M, signals a significant advancement in neurotechnology that could reshape healthcare and attract substantial investment in brain-computer interface innovations.

Analytics Insight: Latest AI, Crypto, Tech News & Analysis

FinancialContent

ETF Trends